The interplay between the immune and central nervous systems in neuronal injury
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Once perceived as a region of limited immune activity, the CNS is now known to be an important site of immune interactions. Activated T cells can infiltrate the blood-brain barrier where they accumulate and proliferate in response to antigen restimulation. These leukocytes express proinflammatory cytokines that help in activating microglia and other immune cells. A profound inflammatory response ensues, which can lead to axonal injury and demyelination. In contrast, other T cells can be neuroprotective. CD4+ Th2 cells secrete anti-inflammatory cytokines and can elicit the production of bioactive neurotrophins from CNS glia. In addition, neurons themselves can contribute to immune system regulation by being targets of neurotoxic T cells or by altering T-cell activity, including the generation of regulatory T cells. The interplay between components of the immune system and CNS contributes both to healthy brain function and to the pathogenesis of neurodegenerative diseases such as multiple sclerosis.
Glossary
- ARD=
- autoimmune rheumatic diseases;
- BBB=
- blood-brain barrier;
- BDNF=
- brain-derived neurotrophic factor;
- EAE=
- experimental autoimmune encephalitis;
- ECM=
- extracellular matrix;
- FGF=
- fibroblast growth factor;
- HPA=
- hypothalamic-pituitary-adrenal;
- IGF=
- insulin-like growth factor;
- IL=
- interleukin;
- IVIG=
- IV immunoglobulin;
- SCI=
- spinal cord injury;
- MHC=
- major histocompatibility complex;
- MMP=
- matrix metalloproteinase;
- M/M=
- monocytes/macrophages;
- NT-3=
- neurotrophin-3;
- NO=
- nitric oxide;
- OPC=
- oligodendrocyte precursor cell;
- PDGF=
- platelet-derived growth factor;
- TLR=
- toll-like receptor;
- TNF=
- tumor necrosis factor.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Articles
Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosisSuhayl Dhib-Jalbut et al.Neurology, June 04, 2007 -
Articles
Interferon-β mechanisms of action in multiple sclerosisSuhayl Dhib-Jalbut, Steven Marks et al.Neurology, December 28, 2009 -
Articles
Dual role of inflammation in CNS diseaseReinhard Hohlfeld, Martin Kerschensteiner, Edgar Meinl et al.Neurology, June 04, 2007 -
Views & Reviews
Interferon beta in the treatment of multiple sclerosisMechanisms of actionV. Wee Yong, Sophie Chabot, Olaf Stuve et al.Neurology, September 01, 1998